Skip to main content
. 2020 May 20;11:981. doi: 10.3389/fimmu.2020.00981

Figure 1.

Figure 1

Median trough immunoglobulin G (IgG) levels and median dose per 4 weeks of immunoglobulin therapy in: (A) patients that completed the 24-month follow-up, (B) patients that switched from subcutaneous immunoglobulin (SCIG) to fSCIG, (C) patients that switched from intravenous immunoglobulin (IVIG) to fSCIG, (D) patients that switched in a ramp-up mode, and (E) patients that switched in a non-ramp-up mode.